The present invention relates to a drug eluting device for preventing and treating restenosis and neointimal formation after vascular procedures and/or implantation of implants comprising an implantable or non-implantable device, such as stent, balloon or graft containing an effective amount of at least one retinoid receptors ligand as active ingredient and a coating system.

A medical device for placement in a body of a mammal is provided. The medical device comprises (1) a polymeric matrix forming the device and defining a lumen through the device, the matrix comprising polymer macromolecules and defining spaces between the polymer macromolecules; (2) a drug contained within at least some of the spaces of the matrix; and (3) a material contained within at least some of the spaces of the matrix to affect diffusion of the drug out of the polymeric matrix when the medical device is placed in the boy of the mammal.

A medical device for insertion into a natural or artificial body opening, such as a urinary catheter is described. The medical device comprises a substrate having a wall enclosing an internal cavity that forms a tubular body. The wall extends between a proximal insertion end and a distal rearward end. The wall comprises at least 30 wt % of natural fibers, such as cellulose fibers. One example medical device is, at least to a large extent, made of paper.

The invention provides compositions featuring chitosan and polyethylene glycol and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the chitosan-PEG compositions can be loaded with one or more antimicrobial agents, including hydrophobic agents, and can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).

Medical devices such as stents, stent grafts, and balloon catheters include a coating layer applied over a modified exterior surface of the medical device. The modified exterior surface comprises an exterior surface of the medical device subjected to a surface modification that decreases a surface free energy of the exterior surface before application of the coating layer an exterior surface. The coating layer comprises a hydrophobic therapeutic agent and at least one additive. The modified exterior surface may affect the release kinetics of the drug from the device, the crystallinity of the drug layer, the surface morphology of the coating and particle shape, or the particle size of drug of a therapeutic layer in the coating layer. For example, the effects caused by the modified exterior surface may increase the retention time and amount of therapeutic agent in tissue.

The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings.

A pharmaceutical composition is described. The pharmaceutical composition includes a polymeric coating composition comprising polymeric nanoparticles dispersed within a polymeric matrix, wherein the polymeric nanoparticles include a first therapeutic agent and a second therapeutic agent. Implantable medical devices coated with the pharmaceutical composition, methods of coating an implantable medical device with the pharmaceutical composition, and methods of treating vascular disease using the pharmaceutical composition are also described.

Medical grade yarns, medical devices constructed of such yarns, and methods for making such yarns and devices are described. Polyester drawn fibers, and more particularly high strength and high tenacity micro polyester fibers for use in medical devices, and methods of preparing the same are provided.

A biocompatible Mg—P coating on the surface of a zinc-based biomedical material, and a preparation method and use thereof are disclosed. In the method, zinc and a zinc alloy are first subjected to surface pretreatment and then soaked in a phosphate solution at a constant temperature to form the Mg—P coating through chemical liquid deposition (CLD). The control on the composition, thickness and surface morphology of the coating is realized by using the CLD method. The biocompatible Mg—P coating has a thickness of 0.5 μm to 50 μm, is dense and uniform, and comprises a main component of zinc-magnesium-phosphate and a small amount of zinc phosphate.

The invention generally relates to compositions comprising degradable polymers and methods of making degradable polymers. Specifically, the disclosed degradable polymers comprise a biodegradable polymer backbone, a nitric oxide linker moiety, and a nitric oxide molecule. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.